DGAP-News

Sangui BioTech: Positive Outlook after Weak Fourth Quarter / Cost Cutting Initiated Inc.:

DGAP-News: Sangui BioTech International Inc. / Key word(s):
Preliminary Results
Sangui BioTech: Positive Outlook after Weak Fourth Quarter / Cost
Cutting Initiated Inc.:

27.08.2015 / 14:00

---------------------------------------------------------------------

Sangui BioTech: Positive Outlook after Weak Fourth Quarter / Cost Cutting
Initiated

Witten, Germany, August 27, 2015 - According to preliminary, unaudited
figures Sangui Biotech International, Inc. yielded revenues from royalties
and product sales of less than USD130,000 in the course of its financial
year 2015, ended June 30, 2015. In the financial year 2014 revenues
amounted to USD133,470. Revenues in the fourth quarter came in at around
USD11,000 (Q4/2014: USD43,729).

Royalties from the licensing agreement regarding the wound treatment
product Granulox engrossed by SanguiBioTech GmbH in the operating currency
EUR, however, increased by 34.4% in the 2015 financial year.

SanguiBioTech GmbH has reacted to the sluggish top line development by
starting a new round of cost cutting involving personnel expenses and
office space as well as reducing patent expenses by giving up marginal
patents, in particular those protecting the cosmetics business.

According to preliminary information provided by global licensee SastoMed
GmbH Granulox sales are expected to increase again slightly in the current
quarter (ending September 30) and more significantly in the December
quarter.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]

Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes
no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise.



---------------------------------------------------------------------

27.08.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


389705 27.08.2015